| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/00007890-198811000-00002 |
| P698 | PubMed publication ID | 3057685 |
| P2093 | author name string | Kahan BD | |
| Grevel J | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cyclosporine | Q367700 | ||
| P304 | page(s) | 631-644 | |
| P577 | publication date | 1988-11-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy | |
| P478 | volume | 46 |
| Q46697433 | A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms |
| Q41786958 | A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation |
| Q35759128 | A review of assay methods for cyclosporin. Clinical implications |
| Q34470498 | An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders |
| Q67486478 | Azoles, a48 llylamines and drug metabolism |
| Q77632844 | Bioequivalence study of Cipol-N (cyclosporine microemulsion preparation) in healthy adults |
| Q34403351 | Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation |
| Q36922221 | Ciclosporin kinetics in children after stem cell transplantation |
| Q33661595 | Clinical aspects of immunologic monitoring |
| Q41201529 | Clinically significant drug interactions with cyclosporin. An update |
| Q34359090 | Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes |
| Q73278434 | Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study |
| Q61654253 | CsA 2-h concentration correlates best with area under the concentration–time curve after allo-SCT compared with trough CsA |
| Q36081370 | Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study |
| Q44052054 | Cyclosporin A monitoring and AUC determination--where do we go? |
| Q40918376 | Cyclosporin clinical pharmacokinetics |
| Q35759193 | Cyclosporin therapeutic drug monitoring--an established service revisited. |
| Q40961292 | Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). |
| Q77369580 | Cyclosporine A: peak or trough level monitoring in renal transplant recipients? |
| Q52956147 | Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. |
| Q67963184 | Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis |
| Q61591067 | Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children |
| Q35528574 | Cyclosporine treatment of inflammatory bowel disease |
| Q67679661 | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection |
| Q42574225 | Development and validation of a HPLC method for dissolution and stability assay of liquid-filled cyclosporine capsule drug products |
| Q77175860 | Early achievement of target cyclosporine levels during initial post-transplant period with a novel dosing strategy |
| Q51686918 | Effect of age and gender on the activity of human hepatic CYP3A |
| Q73277978 | Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients |
| Q44461519 | Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans |
| Q37977355 | Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity |
| Q35711382 | Evolution of the therapeutic drug monitoring of cyclosporine |
| Q79819422 | Experience with cyclosporine |
| Q61812862 | FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation |
| Q77369559 | Feasibility of changing therapeutic cyclosporine monitoring from C(0) to C(2) in stable renal recipients: narrower coefficient of variation with C(2) monitoring |
| Q37945385 | Fifty years in the vineyard of transplantation: looking back |
| Q73013003 | Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection |
| Q77175762 | High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection |
| Q72753027 | Immunosuppressive agents |
| Q44256929 | Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients |
| Q77322677 | Improving the therapeutic monitoring of cyclosporin A |
| Q70768263 | Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level |
| Q54277588 | Insensitivity to cyclosporine may explain the HLA-DRw6 recipient effect |
| Q44812525 | Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune |
| Q73869051 | Mass conversion from Sandimmun to Sandimmun Neoral: 1 1/2-year experience |
| Q40785466 | New immunosuppressive agents for pediatric transplantation |
| Q70709956 | On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation |
| Q43672150 | Once-a-day oral dosing regimen of cyclosporin A: combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates |
| Q57703989 | Optimization of cyclosporine therapy in kidney transplantation |
| Q43828405 | Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? |
| Q43828391 | Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. |
| Q36496718 | Optimizing the use of cyclosporin in allogeneic stem cell transplantation |
| Q71041955 | Pediatric renal transplantation |
| Q35572368 | Pharmacodynamic monitoring of cyclosporin |
| Q38018027 | Pharmacokinetic drug interactions with cyclosporin (Part II). |
| Q43978086 | Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia |
| Q77175820 | Pharmacokinetic studies of oral and intravenous cyclosporine in prekidney transplant patient |
| Q46830629 | Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients |
| Q38723018 | Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center |
| Q70145003 | Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations |
| Q40714436 | Prevention and management of the adverse effects associated with immunosuppressive therapy |
| Q38015284 | Principles of immunosuppression. |
| Q72753037 | Renal transplantation |
| Q77176891 | Role of therapeutic drug monitoring of rapamycin |
| Q41549146 | Switching between cyclosporin formulations. What are the risks? |
| Q34299495 | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver |
| Q34421473 | The hepatotropic influence of cyclosporine |
| Q34660691 | Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? |
| Q79819453 | Use of cyclosporine in renal transplantation |
| Q38464536 | Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts |
Search more.